Valitic's 2M Customer Milestone: The Strategy Fueling a Biotech Hybrid

NEW YORK, NY – July 29, 2026 – When a skincare brand announces it has surpassed two million customers, it’s a notable event in the hyper-competitive beauty industry. For Valitic, the flagship brand of Innocan Pharma’s subsidiary B.I. Sky Global, this milestone is more than just a marketing win; it’s a critical validation of a much larger, more complex corporate strategy. While customers are buying Kojic acid soaps and Vitamin C serums, they are simultaneously funding a long-term play in the pharmaceutical world: the development of a novel, non-opioid pain management therapy.

Innocan Pharma, a Canadian-Israeli company, operates a unique dual-engine model. One engine is the fast-moving, high-margin world of direct-to-consumer (DTC) wellness products, exemplified by Valitic’s recent success. The other is the slow, capital-intensive, and high-stakes realm of biotech research. The announcement that Valitic has captured a significant customer base offers a clear signal in the noise: the consumer engine is firing on all cylinders, providing the financial horsepower needed to propel the company’s deeper scientific ambitions forward.

The Digital Playbook for Mass-Market Scale

Valitic’s ascent was not accidental. It is the result of a meticulously executed digital strategy in the world’s most challenging e-commerce arena. The brand’s success hinges on a blend of targeted product development and aggressive, data-informed online marketing. Rather than pursuing a traditional retail footprint, Valitic has focused its efforts on dominant e-commerce platforms like Amazon, where it can directly reach and respond to consumer demand.

"This a remarkable achievement and validates our strategy of combining innovative product development with data-driven digital marketing," said Roni Kamhi, CEO of B.I. Sky Global Ltd. This approach is evident in Valitic’s product line, which zeroes in on specific, high-demand consumer needs. Its hero products, particularly the Kojic Acid soap line, are formulated to address common concerns like dark spots and uneven skin tone, leveraging well-known ingredients such as Vitamin C, Retinol, and Turmeric. This product-market fit is amplified by an accessible pricing strategy, often featuring multi-packs and discounts that encourage trial and bulk purchases, a classic e-commerce tactic to drive volume and customer acquisition.

This focus on digital channels allows for rapid iteration and responsiveness. By analyzing sales data, customer reviews, and search trends, the company can quickly identify market gaps and consumer desires, feeding that intelligence directly back into product development. It’s a closed-loop system that minimizes waste and maximizes relevance—a crucial advantage in a market where trends can shift in a matter of weeks.

Cultivating Trust Beyond the Transaction

Attracting two million customers is one challenge; earning their trust is another entirely. In an era of ingredient-savvy consumers and heightened skepticism, brand loyalty is a hard-won currency. Valitic appears to be building this trust not through celebrity endorsements or splashy campaigns, but through product performance and transparency.

"Consumer trust is earned one customer at a time," Kamhi noted, emphasizing that the milestone reflects product quality and a deep understanding of consumer needs. This aligns perfectly with the broader macro-trends shaping the $35 billion U.S. skincare market. Today’s consumers are driving a “medicalization of skincare,” prioritizing clinical efficacy and ingredient transparency over legacy brand names. They are scrutinizing labels, demanding clean formulations, and seeking out products that deliver tangible results. Valitic's strategy of highlighting recognizable, active ingredients and achieving favorable ratings from platforms like SkinSAFE for being free of common allergens speaks directly to this discerning audience.

The shift from vague “anti-aging” promises to a more sophisticated focus on “skin longevity” and targeted treatments for issues like hyperpigmentation creates a fertile ground for brands that deliver on their claims. Valitic's success suggests it has effectively tapped into this demand, creating a perception of reliability and efficacy that encourages repeat purchases and positive word-of-mouth in the powerful ecosystem of online reviews.

How Wellness Success Powers Broader Ambitions

The most compelling aspect of Valitic’s growth lies within the corporate structure of Innocan Pharma. The revenue generated by the wellness division—which posted US$6.47 million in Q1 2026, a nearly 30% increase from the previous quarter, and US$26.6 million for the full 2025 fiscal year with impressive gross margins—is not just profit. It is strategic capital.

This cash flow helps fuel Innocan’s other, more ambitious engine: a pharmaceutical platform developing a CBD-loaded liposome technology (LPT-CBD). The goal is to create a long-acting, injectable therapy for chronic pain, a potential game-changer in a field desperate for non-opioid alternatives. This is a long, arduous, and expensive journey fraught with regulatory hurdles and clinical risk. However, Innocan has made steady progress, engaging in positive pre-Investigational New Drug (pre-IND) meetings with the U.S. FDA and securing an accelerated 505(b)(2) regulatory pathway, signaling a viable route to market.

This dual-strategy provides a powerful hedge. While the pharmaceutical arm pursues a high-risk, high-reward breakthrough, the wellness division generates predictable, near-term revenue. This model de-risks the company’s overall profile, reducing its reliance on dilutive capital raises that are typical for early-stage biotech firms. For investors, it presents a hybrid opportunity: exposure to the explosive potential of a successful drug therapy, backstopped by a profitable and growing consumer goods business.

Iris Bincovich, CEO of Innocan Pharma, framed the Valitic milestone as a demonstration of this strategy in action. "We believe this achievement marks an important step toward creating sustainable long-term value for our shareholders," she stated. It’s a clear acknowledgment that the sales of skincare products on Amazon are intrinsically linked to the future of the company’s most advanced scientific programs. While the path for any company attempting to innovate in both consumer markets and pharmaceuticals is challenging, Innocan's model shows how commercial success today can be strategically leveraged to build the breakthroughs of tomorrow.